

Cite this: *RSC Adv.*, 2017, 7, 25710

Synthesis, biological evaluation and molecular docking of spirofurochromanone derivatives as anti-inflammatory and antioxidant agents†

D. Ashok,^a E. V. L. Madhuri,^a M. Sarasija,^b S. Sree Kanth,^c M. Vijjulatha,^c Malini D. Alaparathi^d and S. R. Sagurthi^{*d}

A series of 2'-substituted-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chroman]-5'(7'H)-one, **5a–i** and **7a–u** have been synthesized using an eco-friendly approach to attain good yields in a shorter reaction time. The structures of novel compounds were characterized by IR, ¹H NMR, ¹³C NMR and mass spectrometry analysis. All the synthesized compounds were evaluated for their biological activity. Compounds **5a**, **5b**, **5c**, **5d**, **5e**, **7g**, **7h**, **7j**, **7l**, **7n** and **7q** were found to have better anti-inflammatory activity in the albumin denaturation technique. All compounds exhibited good antioxidant activity by DPPH radical scavenging assay and most compounds showed activity in a hydrogen peroxide assay. Molecular docking scores as well biological assays results suggested that compound **7h** has better anti-inflammatory activity among the synthesized compounds.

Received 7th February 2017

Accepted 30th April 2017

DOI: 10.1039/c7ra01550j

rsc.li/rsc-advances

1 Introduction

Reactions occurring in several types of tissue injuries, infections, immunologic stimulation as a defense against foreign or altered endogenous substances is termed as inflammation. The release of chemical mediators from injured tissue and migrating cells triggers inflammation. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) will be generally prescribed to overcome such physiological disturbances. The activity of NSAIDs in inflammatory diseases does not seem to be only due to the inhibition of the production of endogenous prostaglandins, but also by preventing the denaturation of proteins (which act as antigens and auto immune disease).¹ Grant *et al.*² stated that non-steroidal anti-inflammatory molecules will stabilize bovine serum albumin (BSA) when exposed to a few degree rises in temperature. Selecting therapeutically interesting molecules without the use of animals or living organisms used to be a challenge to the scientific community, which was well addressed by Williams *et al.*³ by developing a technique of stabilizing thermal immunogenic bovine serum albumin by

natural products. It is also revealed that a range of extracts and compounds with various biological properties can convey the stability to the protein.⁴ Thus, rather than just detecting non-steroidal anti-inflammatory agents, the bovine serum albumin denaturation assay could have a wider application.

Biaryl units as molecular components has attracted enormous interest and their syntheses have been widely carried out and have yielded innumerable compounds with diverse biological activities such as: anti-inflammatory, antimicrobial, antifungal, antiproliferative, antidiabetic, immunosuppressant, analgesic, antioxidant.⁵ The Suzuki cross-coupling reaction, which represents an attractive and alternative methods that use organometallic species for the construction of unsymmetrical biaryl compounds, involves air and moisture stable organoboranes that possess relatively low toxicity and also has broad functional group tolerance. Catalysts used in the Suzuki reaction have been traditionally based on homogeneous palladium phosphine complexes.⁵ The study for improving the reactivity of Suzuki reactions, water or aqueous-organic mixtures has received attention due to the ability of the base to dissolve in water for activating arylboronic acids.⁶

Benzofurans are interesting oxygen containing heterocycles which are ubiquitous in nature and show a wide range of biological activities,⁷ as analgesics,⁸ antidepressants,⁹ antitumor agent.¹⁰ Similarly chromanone derivatives, in particular 2-spirochroman-4(1H)-ones are embodied in many bio-active molecules (Fig. 1) and possess various biological activities which include antiarrhythmic,¹¹ anti-HIV,¹² antidiabetic, ACC inhibitor,¹³ vanilloid receptor antagonist, growth hormone secretagogues,¹⁴ histamine receptor antagonist, antiviral¹⁵ and anti-inflammatory.¹⁶ Spirochromanone ring system represents an

^aGreen and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana, India-500007. E-mail: ashokdou@gmail.com


^bDepartment of Chemistry, Satavahana University, Karimnagar, Telangana, India-505001

^cMolecular Modeling and Medicinal Chemistry Group, Department of Chemistry, University College of Science, Osmania University, Hyderabad, Telangana, India-500007


^dDepartment of Genetics, Drug Design & Molecular Medicine Lab, Osmania University, Hyderabad, Telangana, India-500007. E-mail: drsomeswar@osmania.ac.in

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra01550j






1'-Benzylspiro[chroman-2,4'-piperidin]-4-one



Nokhel




Visnagin

Fig. 1 Bioactive molecules.

important class of naturally occurring substances characterized by highly pronounced biological properties.

The combination of two or more pharmacophores or chemical entities either linked with one another or fused together to create a new molecule is referred to as molecular hybridization,¹⁷ which aims to combat drug resistance and enrich existing arsenals of anti-infective agents.¹⁸ The selection of the pharmacophores is based upon their known bioprofiles, with the hope that the resulting hybrid molecules may exhibit synergistic or additive pharmacological activities.¹⁹

Potential availability of benzofuran and spirochromanone made us to synthesize some new spirofurochromanone-biaryl derivatives using Suzuki coupling by the combination of two green chemistry principles, namely microwave assisted synthesis and aqueous phase reactions. Hybrid compounds containing benzofuran and spirochromanone moieties, called spirofurochromanone, due to combined effect may exhibit better biological profile. Enabling technologies for organic syntheses such as microwave, aqueous phase reactions or green solvents have changed organic chemistry in terms of efficiency,



5a: X = CH₂, R = H **5b:** X = NBoc, R = H **5c:** X = Nil, R = H

5d: X = CH₂, R = Br **5e:** X = NBoc, R = Br **5f:** X = Nil, R = Br

5g: X = CH₂, R = Cl **5h:** X = NBoc, R = Cl **5i:** X = Nil, R = Cl

Scheme 1 Synthesis of compounds 5a–i. Reagents and conditions: (i) toluene, pyrrolidine, reflux, 3 h. (ii) (method a) K₂CO₃, acetone, Δ (method b) K₂CO₃, MWI.



work-up and speed. Microwave assisted organic synthesis leads to rate enhancement with excellent reproducibility, improved yields and less side reactions compared to conventional heating.²⁰

In continuation to our efforts^{21–23} to synthesize new biaryl heterocyclic derivatives using eco-friendly approach, we have synthesized spirofurochromanone derivatives **5a–i** and **7a–u** from compounds **3a–c** using microwave irradiation and conventional heating. All the compounds were well characterised by spectral data. Synthesized spirofurochromanone were screened for *in vitro* scavenging activity utilizing

hydrogen peroxide and DPPH assay. These tested compounds shown high scavenging activity when compared with standard ascorbic acid.

2 Results and discussions

2.1 Chemistry


The desired spirofurochromanone scaffolds were synthesized in three steps as outlined (Scheme 1). Selective synthesis of monospiro chromanone derivatives **3a–c** were achieved from diacyl resorcinol **1** with cyclic alkanones **2a–c** involving Kabbe condensation with pyrrolidine as base and toluene as solvent.²⁴ Further reaction of **3a–c** with 4'-substituted phenacyl bromide **4a–c** in presence of potassium carbonate as base resulted in spirofurochromanone **5a–i** with good yields in conventional heating and microwave irradiation methods as shown in Table 1. Finally the target compounds **7a–u** were synthesized by reaction of compound **5d–f** with arylboronic acids **6a–g** in conventional heating and microwave irradiation methods (Scheme 2).

In our initial attempts in conventional method for the synthesis of compound **7a** from **5d**, based on the previous experience of Suzuki coupling reactions in our research group,²⁵ we started with 10 mol% Pd(PPh₃)₄ as catalyst, Na₂CO₃ as a base and 1 equiv. of phenylboronic acid **6a** as a model reaction at 80 °C for 10 h under N₂ atmosphere in DMF, ethanol as well as in dioxane separately, which resulted in very poor yields. Among them ethanol was found to be a better solvent with relatively better yield. Literature reports shows that addition of water as co-solvent to the polar aprotic solvents greatly improves the rate of reaction.²⁶

Table 1 Comparison of yields of compounds **5a–i** at different synthetic conditions

Entry	X	R	Mp, °C	Conventional heating		Microwave irradiation	
				Time, h	Yield ^a , %	Time, min	Yield ^a , %
5a	CH ₂	H	128–130	3	57	5	82
5b	NBoc	H	220–222	4	57	8	84
5c	Nil	H	78–70	3	35	5	71
5d	CH ₂	Br	148–150	3	58	5	83
5e	NBoc	Br	224–226	4	70	8	80
5f	Nil	Br	130–132	3	50	5	77
5g	CH ₂	Cl	126–128	3	70	5	79
5h	NBoc	Cl	218–220	4	72	8	77
5i	Nil	Cl	125–127	3	55	5	80

^a Isolated yield.



7a: X= CH₂, Ar = Ph

7b: X= CH₂, Ar = 4-CHO-C₆H₄

7c: X= CH₂, Ar = 4-Cl- C₆H₄

7d: X= CH₂, Ar = 4-CH₃- C₆H₄

7e: X= CH₂, Ar = 1-Naphthyl

7f: X= CH₂, Ar = 3,5-diCl- C₆H₃

7g: X= CH₂, Ar = 4-F- C₆H₄

7h: X= NBoc, Ar = Ph

7i: X= NBoc, Ar = 4-CHO- C₆H₄

7j: X= NBoc, Ar = 4-Cl- C₆H₄

7k: X= NBoc, Ar = 4-CH₃- C₆H₄

7l: X= NBoc, Ar = 1-Naphthyl

7m: X= NBoc, Ar = 3,5-diCl-C₆H₃

7n: X= NBoc, Ar = 4-F- C₆H₄

7o: X= Nil, Ar= Ph

7p: X= Nil, Ar= 4-CHO- C₆H₄

7q: X= Nil, Ar= 4-Cl- C₆H₄

7r: X= Nil, Ar= 4-CH₃- C₆H₄

7s: X= Nil, Ar = 1-Naphthyl

7t: X= Nil, Ar = 3,5-diCl- C₆H₃

7u: X= Nil, Ar = 4-F- C₆H₄

Scheme 2 Synthesis of compounds **7a–u**.



Thus we decided to check with combination of solvents with water. Using 1 : 1 solvent water mixture, the reaction proceeded well furnishing improved yields in shorter time as shown in Table 2. The Suzuki coupled products were obtained in shorter time and high yield in 1 : 1 : 1 solvent mixture of ethanol, toluene and water. Using the same solvents, reaction was carried out in a sealed tube by conventional heating and the yields are listed in Table 2. Encouraged by the results obtained, we subsequently attempted to carry out the reaction under mild conditions and reduced reaction time by the application of microwave irradiation.

Microwave irradiation at 180 W, keeping similar conditions the reactions were completed within few minutes and increased yields of the product were obtained. Having established the optimal conditions for the reaction, compounds **5d**, **5e** and **5f**

were subjected to react with different substituted arylboronic acids **6a–g** to give **7a–u**. The comparative studies based on the optimization of both methods are reflected in Table 3. All the compounds synthesized were well characterized by spectral data.

2.2 Biological activity

All the newly synthesized compounds **5a–i** and **7a–u** were screened for their anti-inflammatory and antioxidant activities. The *in vitro* anti-inflammatory and antioxidant activities of the synthesized **5a–i** and **7a–u** are tabulated (Tables 4 and 5).

2.2.1 Anti-inflammatory studies. The anti-inflammatory activity of the precursors **5a–i** and synthesized compounds **7a–u** were tested for their *in vitro* anti-inflammatory activity by using

Table 2 Screening of different solvents

Entry	Solvent	Conventional heating		Conventional heating in sealed pressure tube		Microwave irradiation	
		Time, h	Yield ^a , %	Time, h	Yield ^a , %	Time, min	Yield ^a , %
7a	DMF	10	10	8	20	40	40
7a	DMF/water (1 : 1)	9	25	7	30	25	40
7a	Dioxane	10	17	8	26	40	37
7a	Dioxane/water (1 : 1)	9	40	7	45	25	55
7a	EtOH	10	30	8	38	40	45
7a	EtOH/water (1 : 1)	9	35	7	40	25	57
7a	EtOH/toluene/water (1 : 1 : 1)	8	70	6	75	20	83

^a Isolated yield.

Table 3 Reaction conditions for synthesis of products **7a–u**

Entry	X	Ar	Mp, °C	Sealed tube, conventional heating		Microwave irradiation	
				Time, h	Yield ^a , %	Time, min	Yield ^a , %
7a	CH ₂	Ph	172–174	6	75	20	83
7b	CH ₂	4-CHO-C ₆ H ₄	168–170	6	74	22	82
7c	CH ₂	4-Cl-C ₆ H ₄	186–188	6	74	20	84
7d	CH ₂	4-Me-C ₆ H ₄	190–192	6	76	20	87
7e	CH ₂	1-Naphthyl	152–154	6	75	20	86
7f	CH ₂	3,5-DiCl-C ₆ H ₃	178–180	6	74	20	85
7g	CH ₂	4-F-C ₆ H ₄	170–172	6	77	22	84
7h	NBoc	Ph	205–207	7	76	23	82
7i	NBoc	4-CHO-C ₆ H ₄	210–212	7	71	25	80
7j	NBoc	4-Cl-C ₆ H ₄	218–220	7	74	23	83
7k	NBoc	4-Me-C ₆ H ₄	224–227	7	77	23	85
7l	NBoc	1-Naphthyl	147–148	7	73	23	84
7m	NBoc	3,5-DiCl-C ₆ H ₃	207–208	7	74	23	86
7n	NBoc	4-F-C ₆ H ₄	208–210	7	75	23	87
7o	Nil	Ph	118–120	6	74	20	86
7p	Nil	4-CHO-C ₆ H ₄	182–184	6	76	21	88
7q	Nil	4-Cl-C ₆ H ₄	138–140	6	75	20	83
7r	Nil	4-Me-C ₆ H ₄	126–128	6	74	20	85
7s	Nil	1-Naphthyl	170–172	6	75	20	84
7t	Nil	3,5-DiCl-C ₆ H ₃	187–188	6	76	20	88
7u	Nil	4-F-C ₆ H ₄	138–140	6	73	20	85

^a Isolated yield.



Table 4 Anti-inflammatory activity of compounds 5a–i and 7a–u

Compound	Anti-inflammatory activity ^a IC ₅₀ (μM mL ⁻¹)	Compound	Anti-inflammatory activity ^a IC ₅₀ (μM mL ⁻¹)
5a	110.58 ± 0.78	7g	97.39 ± 0.76
5b	77.94 ± 1.00	7h	77.11 ± 0.66
5c	132.0 ± 1.02	7i	142.31 ± 0.64
5d	105.61 ± 0.59	7j	108.97 ± 0.85
5e	98.46 ± 0.90	7k	120.48 ± 0.88
5f	159.17 ± 1.00	7l	108.49 ± 0.74
5g	127.55 ± 0.86	7m	152.77 ± 0.89
5h	140.48 ± 1.29	7n	116.10 ± 1.10
5i	152.81 ± 0.92	7o	130.92 ± 0.94
7a	154.07 ± 0.71	7p	137.42 ± 0.76
7b	118.3 ± 0.95	7e	102.82 ± 0.70
7c	164.09 ± 1.15	7r	172.04 ± 0.93
7d	140.85 ± 1.02	7s	168.42 ± 0.74
7e	170.41 ± 0.74	7t	145.33 ± 0.91
7f	128.99 ± 0.87	7u	127.59 ± 0.75
Aspirin	116.48 ± 0.98		

^a Values are mean ± SD of three replicates.

Table 5 Antioxidant DPPH activity of compounds 5a–i and 7a–u

Compound	DPPH ^a IC ₅₀ (μg mL ⁻¹)	Compound	DPPH ^a IC ₅₀ (μg mL ⁻¹)
5a	8.16 ± 1.41	7g	3.93 ± 1.06
5b	6.84 ± 1.51	7h	63.92 ± 1.02
5c	8.81 ± 1.24	7i	56.17 ± 1.17
5d	2.64 ± 1.14	7j	10.16 ± 1.25
5e	10.16 ± 1.39	7k	6.84 ± 1.32
5f	8.81 ± 1.06	7l	4.86 ± 1.56
5g	12.4 ± 0.98	7m	6.84 ± 1.38
5h	8.81 ± 1.15	7n	37.04 ± 1.43
5i	3.93 ± 1.07	7o	66.2 ± 1.55
7a	39.64 ± 1.16	7p	39.64 ± 1.17
7b	6.84 ± 1.31	7q	76.64 ± 0.93
7c	11.03 ± 1.89	7r	47.5 ± 1.01
7d	13.5 ± 1.04	7s	47.49 ± 1.23
7e	11.03 ± 1.12	7t	80.59 ± 1.19
7f	6.84 ± 1.29	7u	66.16 ± 1.32
Ascorbic acid	145.4 ± 0.27		

^a Values are mean ± SD of three replicates.

inhibition of albumin denaturation technique, for the determination of IC₅₀ values (concentration of an inhibitor where the response (or binding) is reduced by half). The results of the activity were compared with the standard drug aspirin. The IC₅₀ values are listed in Table 4. The synthesized compounds have IC₅₀ values in the micromolar range, varying from 77.11 to 172.04. Among them, ten compounds 5a, 5b, 5d, 5e, 7g, 7h, 7j, 7l, 7n and 7q with IC₅₀ values varying from 77.11 to 116.10 μM possess relatively better inhibitory efficiency compared to that of standard aspirin (IC₅₀ = 116.48 μM).

2.2.2 Anti oxidant studies

2.2.2.1 DPPH radical-scavenging assay. The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical-scavenging assay is usually

used to evaluate the abilities of new compounds to capture free radicals by producing the reduced form DPPH-H through a hydrogen-donating action. It was performed in order to determine the antioxidant potential.²⁷

DPPH is a stable nitrogen-centered free radical. Its reaction rates correlate directly with antioxidant activity, the higher the rate, the more effective the antioxidant.²⁸ A freshly prepared DPPH solution shows a deep purple color with an absorption maximum at 517 nm. When the purple color changes to yellow, it leads to decreased absorbance. This is because of the antioxidant molecule reducing the DPPH free radical through donation of hydrogen atom. Instantaneous or concomitant decrease in absorbance would be indicative of potent antioxidant activity by the compound.²⁹

In this study, we investigated the antioxidant properties of spirofurochromanone derivatives using DPPH scavenging activity with respect to the standard ascorbic acid and using a spectrometric assay.

2.2.2.2 Hydrogen peroxide scavenging assay. Several reactive species are known to produce in excess during the inflammatory processes, the ROS peroxy radical (ROO[•]), HO[•], O₂^{•-}, H₂O₂, and HOCl play important roles in their pathophysiological conditions, hydrogen peroxide (H₂O₂) is a biologically important, non-radical reactive oxygen species (ROS) that can influence several cellular processes, which makes them potential targets for the therapy of inflammation.³⁰ *In vitro* antioxidant activities of synthesized compounds were evaluated against hydrogen peroxide and were compared with standard ascorbic acid. Our results reveal that these compounds exhibit better radical scavenging activities. The results of antioxidant activity of spirofurochromanone are shown in Table 6.

2.2.3 SAR studies

2.2.3.1 Anti-inflammatory activity. In the series of compounds 5a–i cyclohexylspiro compounds exhibited mild

Table 6 Antioxidant H₂O₂ activity of compounds 5a–i and 7a–u

S. no.	Compound	IC ₅₀ ^a value (μg mL ⁻¹)	Compound	IC ₅₀ ^a value (μg mL ⁻¹)
1	5a	112.05 ± 0.88	7g	96.65 ± 0.79
2	5b	73.67 ± 0.15	7h	44.73 ± 0.49
3	5c	25.12 ± 0.26	7i	42.26 ± 0.41
4	5d	83.14 ± 0.13	7j	80.05 ± 0.16
5	5e	98.55 ± 0.18	7k	42.26 ± 0.41
6	5f	41.11 ± 1.23	7l	82.21 ± 0.61
7	5g	68.6 ± 0.54	7m	78.05 ± 0.65
8	5h	77.05 ± 0.34	7n	43.04 ± 0.50
9	5i	51.42 ± 0.69	7o	49.51 ± 0.17
10	7a	103.95 ± 0.9	7p	93.12 ± 0.23
11	7b	70.93 ± 0.38	7q	35.51 ± 0.07
12	7c	32.11 ± 0.38	7r	35.51 ± 0.07
13	7d	62.05 ± 0.74	7s	62.03 ± 0.77
14	7e	51.21 ± 0.35	7t	78.05 ± 0.22
15	7f	37.11 ± 0.41	7u	76.5 ± 0.24
			Ascorbic acid	77.13 ± 0.87

^a Values are mean ± SD of three replicates.



Table 7 Dock score of molecules at different binding site in BSA

Molecule	Dock score in kcal mol ⁻¹				
	Site 1	Site 2	Site 3	Site 4	Site 5
5a	-5.04465	-3.76925	-3.22027	-1.97144	-5.34381
5b	-4.91124	-3.69292	-2.36801	-1.32099	-6.55207
5c	-5.17773	-3.79194	-3.39834	0.802319	-6.12478
5d	-5.14163	-4.0252	-2.04788	0.990484	-6.02642
5e	-4.25431	-3.73157	-2.89809	-1.93373	-4.97476
5f	-5.33577	-3.83444	-3.39073	0.022163	-5.15616
5g	-6.90317	-3.67625	-2.97721	1.069312	-5.77175
5h	-4.28098	-3.25556	-3.15456	0.50295	-6.799
5i	-6.28092	-3.9708	-3.3511	-0.73673	-6.35011
7a	-5.66842	-4.50547	-3.2195	-2.63023	-6.64511
7b	-5.24438	-3.09017	-3.44921	-0.71678	-7.00437
7c	-5.91122	-3.45821	-2.0643	-2.46974	-7.34291
7d	-5.85966	-3.22219	-1.79908	-1.40511	-6.77104
7e	-7.25977	-4.21203	0.528595	-2.32848	-6.20783
7f	-6.07993	-3.94704	-1.57723	-3.23294	-6.81214
7g	-6.13347	-4.7289	-3.18466	1.503116	-7.29907
7h	-6.74828	-3.78363	-3.95033	-3.43081	-6.0202
7i	-5.42021	-3.15689	-2.20818	-3.40362	-6.66791
7j	-6.89574	-3.61415	-2.67466	-0.57856	-6.67635
7k	-6.17567	-4.04447	-1.78585	-1.43157	-6.52291
7l	-6.59588	-4.43139	-0.44855	-2.04492	-5.46365
7m	-4.5574	-3.97825	-1.5371	-2.85352	-5.66012
7n	-7.01527	-5.64609	-1.0642	-2.98835	-6.32379
7o	-5.5679	-4.59082	-3.14312	-0.16728	-6.54276
7p	-5.22365	-2.67248	-3.32493	-1.96602	-6.74707
7q	-6.75491	-4.53187	-2.50503	-2.28726	-6.61332
7r	-6.02244	-3.42691	-3.08999	-2.80693	-6.5254
7s	-6.41682	-3.98382	-2.45205	-0.77139	-6.29255
7t	-5.87745	-3.0637	-3.17249	-2.34786	-6.92566
7u	-6.50778	-4.66838	-3.28726	-2.36884	-6.51469

anti-inflammatory activity, *N*-Bocpiperidinylspiro compound **5b** has better activity with IC₅₀ value 77.9 and the activity decreases with the change in the substitution at 4th carbon of

2'-benzoyl group with bromo (**5e**, IC₅₀ value 98.4) or chloro (**5h**, IC₅₀ value 140.4) groups. Among the Suzuki cross coupled products **7a-u**, *N*-Bocpiperidinylspiro derivatives **7h-n** show better activity when compared to cyclohexylspiro derivatives **7a-g** and cyclopentylspiro derivatives **7o-u**. Among *N*-Bocpiperidinylspiro compounds **7h** (IC₅₀ value 77.1) exhibited better activity when compared to other substitutions on the biaryl group.

2.2.3.2 Antioxidant activity

2.2.3.2.1 DPPH radical scavenging activity. Compounds **5a-i**, showed good antioxidant activity compared with the standard ascorbic acid. Compounds **5d** and **5i** have better activity while **5a**, **5c**, **5f**, **5h** have almost same activity. Cyclopentylspiro derivatives **7o-u** among the biaryl series of compounds **7a-u** show mild antioxidant activity whereas the series of *N*-Bocpiperidinylspiro and cyclohexylspiro compounds exhibit better activity. **7a-g** compounds have better IC₅₀ values ranging from 3 to 39 owing to the presence of the substituent on the phenyl group of biaryl compound.

2.2.3.2.2 Hydrogen peroxide scavenging assay. Compounds **5b-c** and **5f-i**, with chlorine and bromine as substituent show better activity as compared with the standard ascorbic acid. Among the Suzuki cross coupled products compared to cyclohexylspiro derivative, *N*-Bocpiperidinylspiro derivative and cyclopentylspiro derivative show better activity without any substituent on the biaryl group. In the series of cyclohexylspiro derivatives **7b-f** exhibits better activity out of which presence of chloro group (**7c**, IC₅₀ value 32.11 and **7f**, IC₅₀ value 37.11) on the biaryl moiety exhibits good activity. Among *N*-Bocpiperidinylspiro derivatives biaryl moieties with CHO, Me and F as substituents exhibit good activity (**7i**, IC₅₀ value 42.26, **7k** IC₅₀ value 42.26, **7n** IC₅₀ value 43.04 respectively). Chloro and methyl substituents on the biaryl groups of the cyclopentylspiro derivatives exhibit good activity (**7q** IC₅₀ value 35.51 and **7r** IC₅₀ value 35.51).

Table 8 Dock score of molecules in bovine serum albumin site-1, site-5 and COX-2

Molecule	Dock score in kcal mol ⁻¹			Molecule	Dock score in kcal mol ⁻¹		
	BSA				BSA		
	Site 1	Site 5	COX-2		Site 1	Site 5	COX-2
5a	-5.044	-5.343	-8.415	7g	-6.133	-7.299	-9.378
5b	-4.911	-6.552	-9.807	7h	-6.748	-6.020	-9.549
5c	-5.177	-6.124	-7.794	7i	-5.420	-6.667	-5.600
5d	-5.141	-6.026	-8.562	7j	-6.89574	-6.676	-8.509
5e	-4.254	-4.974	-8.998	7k	-6.17567	-6.522	-5.329
5f	-5.335	-5.156	-7.424	7l	-6.59588	-5.463	-5.522
5g	-6.903	-5.771	-7.689	7m	-4.5574	-5.660	-9.519
5h	-4.280	-6.799	-7.055	7n	-7.01527	-6.323	-5.839
5i	-6.280	-6.350	-6.919	7o	-5.5679	-6.542	-8.001
7a	-5.668	-6.645	-7.839	7p	-5.22365	-6.747	-8.249
7b	-5.244	-7.004	-7.655	7q	-6.75491	-6.613	-9.686
7c	-5.911	-7.342	-8.111	7r	-6.02244	-6.525	-9.150
7d	-5.859	-6.771	-9.257	7s	-6.41682	-6.292	-9.478
7e	-7.259	-6.207	-5.922	7t	-5.87745	-6.925	-8.230
7f	-6.079	-6.812	-4.634	7u	-6.50778	-6.514	-9.276






Fig. 2 (a) Molecule 7h docked at site-5 of BSA. (b) Molecular interaction of molecule 7h showing hydrogen bond interaction with Leu 480, Val 481 and Arg 208, electrostatic interaction with Lys 350 and Glu 353.




Fig. 4 (a) Molecule 7h docked at active site of COX-2. (b) Molecular interaction of molecule 7h showing π - π interaction with Tyr 341 and hydrophobic interaction Gly 512 and Ala 513.




Fig. 3 Ligand interaction diagram of molecule 7h docked at site-5 of BSA showing hydrogen bond interaction with Leu 480, Val 481 and Arg 208, electrostatic interaction with Lys 350 and Glu 353 [distance are mentioned in Å].



Table 9 ADME properties of molecule

Molecule	QP $\log P_{o/w}^a$	QP $\log S^b$	QP $\log BB^c$	QP _{PMDCk} ^d	Percent human oral absorption ^e
5a	4.022	-5.314	-0.453	643.955	100
5b	4.601	-6.753	-0.995	280.644	100
5c	3.756	-4.981	-0.46	616.566	100
5d	4.604	-6.194	-0.289	1709.413	100
5e	5.19	-7.652	-0.841	744.903	81.033
5f	4.309	-5.807	-0.285	1679.254	100
5g	4.528	-6.082	-0.299	1589.697	100
5h	5.111	-7.531	-0.849	692.753	80.568
5i	4.23	-5.687	-0.294	1561.757	100
7a	5.711	-7.481	-0.612	643.259	100
7b	4.579	-6.945	-1.543	103.589	96.205
7c	6.212	-8.234	-0.456	1588.787	100
7d	6.033	-8.079	-0.638	643.102	100
7e	6.65	-8.631	-0.646	642.485	95.54
7f	6.721	-9.017	-0.302	3911.802	95.966
7g	5.951	-7.857	-0.505	1164.676	100
7h	6.285	-8.904	-1.183	280.243	87.434
7i	5.149	-8.358	-2.202	45.132	67.651
7j	6.795	-9.687	-1.036	692.527	90.425
7k	6.612	-9.519	-1.219	280.159	89.347
7l	7.236	-10.104	-1.234	280.245	93.003
7m	7.295	-10.439	-0.886	1704.24	93.351
7n	6.525	-9.28	-1.078	507.476	88.843
7o	5.448	-7.157	-0.623	615.852	100
7p	4.316	-6.621	-1.547	99.175	94.352
7q	5.954	-7.926	-0.468	1521.395	100
7r	5.775	-7.772	-0.651	615.837	100
7s	6.387	-8.307	-0.657	615.107	100
7t	6.418	-8.605	-0.297	3842.145	94.06
7u	5.688	-7.533	-0.516	1115.143	100

^a Predicted octanol/water partition coefficient $\log P$ (acceptable range—2.0–6.5). ^b Predicted aqueous solubility in mol L^{-1} (acceptable range—6.5–0.5). ^c Predicted blood brain barrier permeability (acceptable range—3–1.2). ^d Predicted apparent MDCK cell permeability in nm s^{-1} (acceptable range: <25 is poor and >500 is great). ^e Percentage of human oral absorption (acceptable range: <25 is poor and >80% is high).

2.3 Molecular docking analysis

BSA consists of 583 amino acid residues present in three homologous α -helical domains (I, II, III). Each domain comprises sub-domain A and sub-domain B. Subdomains IIA, IIIA and IB among them are known as Sudlow's site I, II and III, respectively (ESI).^{31–33} To determine the binding interaction of the molecules with bovine serum albumin molecular docking analysis was performed on five binding cavities obtained from site map. Analysis of dock score reveals that the binding affinity of these molecules is more towards the site-5 and site-1 as compared to the other hydrophobic cavities, site-5 and site-1 correspond to drug binding site I and site II.^{31–39} Dock score of molecules at site-5 and site-1 along with the dock score of the molecules which were docked into COX-2 (one of the target for anti-inflammatory) to check the possible mode of interaction is provided in Table 8 (the dock score for molecules at all site is provided in Table 7). Binding energy of the molecules at site-5 ranged between -7.342 to -4.974 kcal mol^{-1} , and for site-1 it ranged between -7.259 to -4.254 kcal mol^{-1} few molecules showed lower and positive binding energies at site-2, site-3 and site-4.

Fig. 2 shows the interaction of molecule 7h with protein at site-5. The molecule showed three hydrogen bond interactions with amino acid residues Leu 480, Val 481 and Arg 208. Two electrostatic interactions were also seen between the π electron cloud of fused aromatic ring and residues Lys 350 and Glu 353. A hydrophobic interaction is also seen with Leu 326. Fig. 3 represents the hydrogen bond interaction with Leu 480, Val 481, Arg 208 and electrostatic interaction with Lys 350, Glu 353 of molecule 7h at site-5 of BSA. Fig. 4 represents the docked conformation of molecule 7h showing π - π interaction with Tyr 341 and hydrophobic interaction Gly 512 and Ala 513 at active site of COX-2. Fig. 5 shows the ligand π - π interaction with Tyr 341 and hydrophobic interaction with Gly 512, Ala 513 of molecule 7h docked at active site of COX-2.




Fig. 5 Ligand interaction diagram of molecule 7h docked at active site of COX-2 showing π - π interaction with Tyr 341 and hydrophobic interaction Arg 106, Gly 512 and Ala 513 [distance are mentioned in Å].



2.3.1 ADME properties. The ADME properties (required pharmacokinetic properties of viable drug compounds) were calculated by Qikprop and analyzed by applying Lipinski's rule of five (Table 9).⁴⁰ Molecular weight less than 650, partition coefficient between octanol and water ($\log P_{o/w}$) between -1 and 6.5 and solubility ($\log S$) greater than -7 . Pmdck greater than 5 and $\log BB$ greater than -3 , these parameter tells us about the ability of the drug to pass through blood brain barrier. Majority of the molecules have the properties in range, partition coefficient of molecules ranged within the acceptable limits expect for two molecules **7l** and **7m** that had values greater than 7 . Cell permeability and blood brain barrier permeability for all molecules is in permissible range. Water solubility and oral absorption for half of the molecules is 100% . The values invariably imply that these molecules are potential drug molecules and can be further optimized for better activity (Fig. 5).

3 Conclusion

In conclusion, we herein report the selective synthesis of monospiro chromanone derivatives **3a-c** from which a series of spirofurochromanones were synthesized following microwave irradiation method and their anti-inflammatory and antioxidant activities were determined. The reaction protocol requires cheap starting materials and is carried out under mild conditions. Compounds **5a**, **5b**, **5c**, **5d**, **5e**, **7g**, **7h**, **7j**, **7l**, **7n** and **7q** were found to be promising with IC_{50} values ranging from 77.11 to $116.10 \mu\text{M mL}^{-1}$ indicates that they are potential anti-inflammatory agents. The binding mode of the synthesized compounds with protein active site was predicted using *in silico* docking. All the compounds **5a-i** and **7a-u** were docked well into the binding pocket of the target protein at all the five sites. The compounds showed good docking at site I and site V.

4 Experimental section

4.1 General methods

All the Suzuki reactions were performed under nitrogen atmosphere using oven dried apparatus. Reactions were monitored by thin layer chromatography (TLC) on silica gel plates (60 F₂₅₄), visualizing with ultraviolet light. Column chromatography was performed on silica gel (60–120 mesh) using distilled hexane, ethyl acetate. ¹H NMR and ¹³C NMR spectra were determined in CDCl₃ solution by using 400 and 100 MHz spectrometers, respectively (Instrument Bruker Avance II 400 MHz). Proton chemical shifts (δ) are relative to tetramethylsilane (TMS, $\delta = 0.00$) as internal standard and expressed in ppm. Spin multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet) as well as bs (broad singlet). Coupling constants (J) are given in hertz. Mass spectra were recorded on GCMS-QP 1000 EX mass spectrometer. Infrared spectra were recorded on a Shimadzu FT-IR-8400s spectrometer. Melting points were determined using Stuart SMP3 melting-point apparatus and are uncorrected. CEM discover microwave reaction vessel equipped with a magnetic stirrer was used for microwave irradiated reactions. The antioxidant property was carried out by using Shimadzu UV-2450 spectrophotometer and

the Perkin Elmer Lambda 750 UV-Visible Spectrophotometer was used to calculate the percentage inhibition for anti-inflammatory activity. Bovine serum albumin used for the anti-inflammatory activity was purchased from Sigma Aldrich.

4.2 General experimental procedure 3a-c

A solution of compound **1** (1 mmol) and pyrrolidine (1 mmol) in toluene was refluxed for 10 min. To the above solution various cycloalkanones **2a-c** (1.5 mmol) were added and the reaction mixture was stirred at 90°C for 4 h, the completion of reaction was monitored by TLC. Compound from the resulting solution was precipitated using 15% NaOH solution, the precipitate was filtered, solid was neutralized with dil. HCl and washed with water, dried in air and recrystallised from ethanol to afford pure monospiro compound **3a-c**.

4.2.1 6-Acetyl-7-hydroxyspiro[chroman-2,1'-cyclopentan]-4-one (3c). White solid; M.F: C₁₆H₁₈O₄; mp: $132-134^\circ\text{C}$; yield: 40% ; IR (KBr, cm⁻¹): 3282, 2935, 1629, 1608, 1225; ¹H NMR (400 MHz, CDCl₃) δ 12.82 (s, 1H), 8.37 (s, 1H), 6.40 (s, 1H), 2.82 (s, 2H), 2.63 (s, 3H), 2.11–2.05 (m, 2H), 1.92–1.84 (m, 2H), 1.78–1.64 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 203.6, 190.4, 168.4, 165.7, 132.0, 115.0, 114.0, 105.2, 91.0, 46.6, 37.6, 26.3, 23.7; MS (ESI mass): m/z , 261 [M + H]⁺.

4.3 General experimental procedure 5a-i

4.3.1 Conventional method. A solution of monospiro compound **3a-c** (1 mmol), substituted phenacyl bromide **4a-c** (1 mmol) and anhydrous K₂CO₃ (3 mmol) in dry acetone were stirred at 60°C for 3 h, the completion of reaction was monitored by TLC. The resulting solution was diluted with water and the precipitate formed was filtered, washed with water, dried in air and was purified by column chromatography (using 5–10% petroleum ether/ethyl acetate) to afford desired compound **5a-i**.

4.3.2 Microwave method. Monospiro compound **3a-c** (1 mmol), substituted phenacyl bromide **4a-c** (1 mmol) was dissolved in acetone and adsorbed over K₂CO₃. This mixture was microwave irradiated at 100 W for 5 min. The resultant mixture was diluted with water. The solid formed was filtered, washed with water, dried in air and purified by column chromatography (using 5–10% petroleum ether/ethyl acetate) to afford desired compound **5a-i**.

4.3.2.1 2'-Benzoyl-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5a). White solid; M.F: C₂₄H₂₂O₄; mp: $128-130^\circ\text{C}$; yield: 82% ; IR (KBr, cm⁻¹): 3082, 2931, 1649, 1618, 1475; ¹H NMR (400 MHz, CDCl₃) δ 8.27 (s, 1H), 8.04–8.02 (d, $J = 7.0$ Hz, 2H), 7.63–7.59 (t, $J = 7.0$ Hz, 1H), 7.52–7.50 (t, $J = 7.0$ Hz, 2H), 7.07 (s, 1H), 2.77 (s, 2H), 2.59 (s, 3H), 2.03–2.01 (m, 2H), 1.75–1.68 (m, 2H), 1.56–1.51 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 192.1, 185.3, 160.0, 158.9, 149.0, 137.7, 132.6, 129.5, 128.3, 127.7, 124.0, 120.9, 118.9, 100.5, 80.6, 48.3, 34.9, 25.1, 21.4, 10.0; MS (ESI mass): m/z , 375 [M + H]⁺.

4.3.2.2 tert-Butyl-7-benzoyl-6-methyl-4-oxo-4,8-dihydro-3H-spiro[cyclopenta[g]chromene-2,4'-piperidine]-1'-carboxylate (5b). White solid; M.F: C₂₈H₂₉NO₆; mp: $220-222^\circ\text{C}$; yield: 84% ; IR (KBr, cm⁻¹): 2972, 1683, 1620, 1246, 1153; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (s, 1H), 8.04–8.02 (d, $J = 7.5$ Hz, 2H), 7.63–7.61 (t, $J = 7.5$ Hz, 1H), 7.52–7.50 (t, $J = 7.0$ Hz, 2H), 7.07 (s, 1H), 2.77 (s, 2H), 2.59 (s, 3H), 2.03–2.01 (m, 2H), 1.75–1.68 (m, 2H), 1.56–1.51 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 192.1, 185.3, 160.0, 158.9, 149.0, 137.7, 132.6, 129.5, 128.3, 127.7, 124.0, 120.9, 118.9, 100.5, 80.6, 48.3, 34.9, 25.1, 21.4, 10.0; MS (ESI mass): m/z , 375 [M + H]⁺.



= 7.5 Hz, 1H), 7.54–7.50 (t, $J = 7.5$ Hz, 2H), 7.10 (s, 1H), 3.88 (bs, 2H), 3.24 (bs, 2H), 2.79 (s, 2H), 2.60 (s, 3H), 2.02–2.06 (m, 2H), 1.69–1.62 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.0, 185.2, 159.3, 158.9, 154.6, 149.2, 137.6, 132.7, 129.5, 128.3, 127.5, 124.5, 121.1, 118.7, 100.6, 79.8, 78.5, 48.1, 34.1, 28.4, 9.9; MS (EI mass): m/z , 475 $[\text{M}]^+$.

4.3.2.3 2'-(4-Bromobenzoyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5c). White solid; M.F: $\text{C}_{23}\text{H}_{20}\text{O}_4$; mp: 68–70 °C; yield: 71%; IR (KBr, cm^{-1}): 2982, 1687, 1618, 1230, 1145; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.04–8.02 (d, $J = 8.5$ Hz, 2H), 7.63–7.59 (m, $J = 8.5$ Hz, 1H), 7.54–7.50 (t, $J = 8.5$ Hz, 2H), 7.02 (s, 1H), 2.90 (s, 2H), 2.59 (s, 3H), 2.13–2.08 (m, 2H), 1.93–1.87 (m, 2H), 1.77–1.66 (m, 4H); MS (ESI mass): m/z , 361 $[\text{M} + \text{H}]^+$.

4.3.2.4 2'-(4-Bromobenzoyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5d). White solid; M.F: $\text{C}_{24}\text{H}_{21}\text{BrO}_4$; mp: 148–150 °C; yield: 83%; IR (KBr, cm^{-1}): 3265, 2927, 1689, 1620, 1336, 1244; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (s, 1H), 7.95–7.93 (d, $J = 8.5$ Hz, 2H), 7.67–7.65 (d, $J = 8.5$ Hz, 2H), 7.07 (s, 1H), 2.77 (s, 2H), 2.62 (s, 3H), 1.75–1.64 (m, 3H), 1.57–1.51 (m, 7H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 183.9, 160.2, 158.8, 148.7, 136.3, 131.1, 128.4, 127.8, 123.9, 121.0, 119.0, 100.5, 80.7, 48.2, 34.9, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 453 $[\text{M} + \text{H}]^+$.

4.3.2.5 tert-Butyl-2-(4-bromobenzoyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (5e). White solid; M.F: $\text{C}_{28}\text{H}_{28}\text{BrNO}_6$; mp: 224–226 °C; yield: 80%; IR (KBr, cm^{-1}): 2974, 1683, 1620, 1246, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 7.95–7.93 (d, $J = 8.7$ Hz, 2H), 7.68–7.66 (d, $J = 8.7$ Hz, 2H), 7.10 (s, 1H), 3.88 (bs, 2H), 3.23 (bs, 2H), 2.80 (s, 2H), 2.62 (s, 3H), 2.06–2.02 (m, 2H), 1.70–1.66 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.0, 183.9, 159.4, 158.8, 154.6, 148.9, 136.1, 131.6, 131.1, 128.2, 127.9, 124.3, 121.2, 118.7, 100.6, 79.9, 78.6, 48.0, 34.1, 28.3, 10.0; MS (ESI mass): m/z , 552 $[\text{M} - \text{H}]^+$.

4.3.2.6 2'-(4-Bromobenzoyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5f). White solid; M.F: $\text{C}_{23}\text{H}_{19}\text{BrO}_4$; mp: 130–132 °C; yield: 77%; IR (KBr, cm^{-1}): 2958, 1689, 1616, 1222, 1143; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 7.95–7.92 (d, $J = 8.7$ Hz, 2H), 7.67–7.65 (d, $J = 8.7$ Hz, 2H), 7.01 (s, 1H), 2.90 (s, 2H), 2.62 (s, 3H), 2.13–2.08 (m, 2H), 1.93–1.87 (m, 2H), 1.75–1.67 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 183.9, 160.9, 158.7, 148.7, 136.3, 131.6, 131.1, 128.4, 127.8, 123.9, 121.3, 119.0, 100.6, 90.7, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 437 $[\text{M} - \text{H}]^+$; HRMS: 438.0446.

4.3.2.7 2'-(4-Chlorobenzoyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5g). White solid; M.F: $\text{C}_{24}\text{H}_{21}\text{ClO}_4$; mp: 126–128 °C; yield: 79%; IR (KBr, cm^{-1}): 2929, 1691, 1618, 1328, 1244, 1143; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (s, 1H), 8.03–8.01 (d, $J = 8.5$ Hz, 2H), 7.50–7.48 (d, $J = 8.5$ Hz, 2H), 7.07 (s, 1H), 2.77 (s, 2H), 2.62 (s, 3H), 1.78–1.65 (m, 3H), 1.56–1.51 (m, 7H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 183.7, 160.2, 158.9, 148.7, 139.1, 135.9, 131.0, 128.6, 123.9, 121.0, 119.0, 100.5, 80.7, 48.2, 34.9, 29.6, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 409 $[\text{M} + \text{H}]^+$.

4.3.2.8 tert-Butyl-2-(4-chlorobenzoyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (5h).

White solid; M.F: $\text{C}_{28}\text{H}_{28}\text{ClNO}_6$; mp: 218–220 °C; yield: 77%; IR (KBr, cm^{-1}): 2922, 1683, 1620, 1244, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.03–8.01 (d, $J = 8.5$ Hz, 2H), 7.51–7.49 (d, $J = 8.5$ Hz, 2H), 7.10 (s, 1H), 3.89 (bs, 2H), 3.23 (bs, 2H), 2.91 (s, 2H), 2.62 (s, 3H), 2.12–2.03 (m, 2H), 1.76–1.67 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.0, 183.7, 159.4, 158.8, 154.6, 148.9, 139.2, 135.7, 131.0, 130.1, 128.7, 124.3, 121.2, 118.7, 100.6, 99.6, 79.9, 78.5, 48.0, 47.5, 28.3, 10.0; MS (ESI mass): m/z , 508 $[\text{M} - \text{H}]^+$.

4.3.2.9 2'-(4-Chlorobenzoyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (5i). White solid; M.F: $\text{C}_{23}\text{H}_{19}\text{ClO}_4$; mp: 125–127 °C; yield: 80%; IR (KBr, cm^{-1}): 2954, 1691, 1616, 1246, 1145; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 8.03–8.00 (d, $J = 8.5$ Hz, 2H), 7.51–7.48 (d, $J = 8.5$ Hz, 2H), 7.02 (s, 1H), 2.90 (s, 2H), 2.62 (s, 3H), 2.13–2.08 (m, 2H), 1.92–1.87 (m, 2H), 1.75–1.66 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 183.7, 160.8, 158.7, 148.8, 139.1, 135.8, 131.0, 128.6, 128.3, 123.9, 121.2, 119.0, 100.6, 90.6, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 393 $[\text{M} - \text{H}]^+$.

4.4 General experimental procedure 7a–u

4.4.1 Conventional method. A degassed mixture of **5d–f** (1.0 mmol), arylboronic acid **6a–g** (1.3 mmol), Na_2CO_3 (3.00 mmol), $\text{Pd}(\text{PPh}_3)_4$ (115 mg, 0.10 mmol) and mixture of 1 : 1 : 1 of toluene, ethanol, water (9 mL) was introduced into a round bottomed flask and heated it at 80 °C for 8 h with constant stirring under nitrogen atmosphere. The resulting solution was diluted with ice water and was extracted with ethyl acetate; the combined organic layers were washed with brine, dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the crude thus obtained was purified using column chromatography to afford titled compound **7(a–u)**.

4.4.1.1 Sealed tube under conventional heating. A mixture of **5d–f** (1.0 mmol), arylboronic acid **6a–g** (1.3 mmol), Na_2CO_3 (3.00 mmol), and mixture of 1 : 1 : 1 of toluene, ethanol, water (9 mL) are degassed in a sealed pressure tube and $\text{Pd}(\text{PPh}_3)_4$ (115 mg, 0.10 mmol) was added followed by degassing and heated it at 80 °C for 6–7 h with constant stirring. The resulting solution was diluted with ice water and was extracted with ethyl acetate; the combined organic layers were washed with brine, dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the crude thus obtained was purified using column chromatography (using 5–10% petroleum ether/ethyl acetate) to afford titled compound **7a–u**.

4.4.2 Microwave method. A mixture of **5d–f** (1.0 mmol), arylboronic acid **6a–g** (1.3 mmol), Na_2CO_3 (3.00 mmol), and mixture of 1 : 1 : 1 of toluene, ethanol, water (9 mL) are degassed in a sealed pressure tube and $\text{Pd}(\text{PPh}_3)_4$ (115 mg, 0.10 mmol) was added followed by degassing. This was introduced into CEM discover microwave reaction vessel equipped with a magnetic stirrer. The vessel was sealed and then placed into the microwave cavity. Initial microwave irradiation of 180 W was used, the temperature being ramped from room temperature to the desired 80 °C temperature. Once this was reached the reaction mixture was heated at this temperature for appropriate time. The resulting solution was diluted with ice water and was



extracted with ethyl acetate; the combined organic layers were washed with brine, dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the crude thus obtained was purified column chromatography to afford titled compound **7a**–**u**.

4.4.2.1 *2'-([1,1'-Biphenyl]-4-carbonyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7a)*. White solid; M.F: $\text{C}_{30}\text{H}_{26}\text{O}_4$; mp: 172–174 °C; yield: 83%; IR (KBr, cm^{-1}): 2929, 1687, 1622, 1290, 1246, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.16–8.14 (d, $J = 8.5$ Hz, 2H), 7.76–7.74 (d, $J = 8.5$ Hz, 2H), 7.68–7.66 (d, $J = 7.2$ Hz, 2H), 7.51–7.47 (t, $J = 7.2$ Hz, 2H), 7.44–7.40 (t, $J = 7.2$ Hz, 1H), 7.01 (s, 1H), 2.78 (s, 2H), 2.63 (s, 3H), 2.04–2.00 (m, 2H), 1.75–1.69 (m, 4H), 1.56–1.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.7, 160.0, 158.9, 149.1, 145.4, 140.0, 136.3, 130.23, 128.9, 128.2, 127.8, 127.3, 127.0, 124.0, 118.9, 100.5, 80.7, 48.3, 34.9, 25.1, 21.4, 10.1; MS (ESI mass): m/z , 451 $[\text{M} + \text{H}]^+$.

4.4.2.2 *4'-(3'-Methyl-5'-oxo-5',6'-dihydrospiro[cyclohexane-1,7'-furo[3,2-g]chromen]-2'-ylcarbonyl)-[1,1'-biphenyl]-4-carbaldehyde (7b)*. White solid; M.F: $\text{C}_{31}\text{H}_{26}\text{O}_5$; mp: 168–170 °C; yield: 82%; IR (KBr, cm^{-1}): 2929, 1687, 1625, 1292, 1220, 1145; ^1H NMR (400 MHz, CDCl_3) δ 10.09 (s, 1H), 8.30 (s, 1H), 8.19–8.17 (d, $J = 8.5$ Hz, 2H), 8.02–8.00 (d, $J = 8.5$ Hz, 2H), 7.85–7.83 (d, $J = 8.2$ Hz, 2H), 7.80–7.78 (d, $J = 8.2$ Hz, 2H), 7.10 (s, 1H), 2.78 (s, 2H), 2.65 (s, 3H), 2.04–2.00 (m, 2H), 1.78–1.69 (m, 4H), 1.57–1.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 191.7, 184.4, 160.1, 158.9, 148.9, 145.8, 143.7, 137.3, 135.7, 130.3, 128.2, 127.9, 127.3, 123.9, 121.0, 118.9, 100.5, 80.7, 48.2, 34.8, 29.6, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 479 $[\text{M} + \text{H}]^+$.

4.4.2.3 *2'-(4'-Chloro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7c)*. White solid; M.F: $\text{C}_{30}\text{H}_{25}\text{ClO}_4$; mp: 186–188 °C; yield: 84%; IR (KBr, cm^{-1}): 2924, 1689, 1616, 1296, 1143; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.72–7.70 (d, $J = 8.7$ Hz, 2H), 7.61–7.59 (d, $J = 8.5$ Hz, 2H), 7.47–7.45 (d, $J = 8.7$ Hz, 2H), 7.09 (s, 1H), 2.78 (s, 2H), 2.63 (s, 3H), 2.04–2.00 (m, 2H), 1.78–1.68 (m, 4H), 1.56–1.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.5, 160.1, 158.9, 149.0, 144.0, 138.4, 136.6, 134.4, 130.3, 129.1, 128.5, 127.9, 126.8, 124.0, 120.9, 118.9, 100.5, 80.7, 48.2, 34.8, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 485 $[\text{M} + \text{H}]^+$.

4.4.2.4 *3'-Methyl-2'-(4'-methyl-[1,1'-biphenyl]-4-carbonyl)spiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7d)*. White solid; M.F: $\text{C}_{30}\text{H}_{25}\text{ClO}_4$; mp: 190–192 °C; yield: 87%; IR (KBr, cm^{-1}): 2931, 1689, 1616, 1294, 1143; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (s, 1H), 8.14–8.12 (d, $J = 8.5$ Hz, 2H), 7.74–7.72 (d, $J = 8.5$ Hz, 2H), 7.59–7.57 (d, $J = 8.0$ Hz, 2H), 7.31–7.29 (d, $J = 8.0$ Hz, 2H), 7.10 (s, 1H), 2.78 (s, 2H), 2.62 (s, 3H), 2.42 (s, 3H), 2.04–2.00 (m, 2H), 1.78–1.65 (m, 4H), 1.56–1.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.7, 160.0, 158.9, 149.1, 145.3, 138.1, 137.0, 136.0, 130.2, 129.6, 127.6, 127.1, 126.7, 124.0, 120.8, 118.8, 100.5, 80.6, 48.2, 34.8, 25.0, 21.4, 21.1, 10.0; MS (ESI mass): m/z , 465 $[\text{M} + \text{H}]^+$; HRMS: 464.19812.

4.4.2.5 *3'-Methyl-2'-(4-(naphthalen-1-yl)benzoyl)spiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7e)*. White solid; M.F: $\text{C}_{34}\text{H}_{28}\text{O}_4$; mp: 152–154 °C; yield: 86%; IR (KBr, cm^{-1}): 2929, 1689, 1622, 1292, 1145; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.21–8.19 (d, $J = 8.5$ Hz, 2H), 7.95–7.90 (m, 3H),

7.68–7.65 (d, $J = 8.5$ Hz, 2H), 7.59–7.46 (m, 4H), 7.13 (s, 1H), 2.78 (s, 2H), 2.67 (s, 3H), 2.04–2.01 (m, 2H), 1.75–1.65 (m, 4H), 1.54–1.47 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.8, 160.0, 158.9, 149.1, 145.4, 139.1, 136.4, 133.7, 131.2, 130.0, 129.7, 128.3, 127.9, 125.9, 125.6, 125.3, 124.0, 120.9, 118.9, 100.5, 80.6, 48.3, 34.8, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 501 $[\text{M} + \text{H}]^+$.

4.4.2.6 *2'-(3',5'-Dichloro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7f)*. White solid; M.F: $\text{C}_{30}\text{H}_{24}\text{Cl}_2\text{O}_4$; mp: 178–180 °C; yield: 85%; IR (KBr, cm^{-1}): 2929, 1687, 1627, 1292, 1147; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.16–8.14 (d, $J = 8.5$ Hz, 2H), 7.70–7.68 (d, $J = 8.5$ Hz, 2H), 7.54–7.53 (d, $J = 1.7$ Hz, 2H), 7.40 (t, $J = 1.7$ Hz, 1H), 7.09 (s, 1H), 2.78 (s, 2H), 2.64 (s, 3H), 2.04–2.00 (m, 2H), 1.75–1.66 (m, 4H), 1.54–1.51 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 184.3, 160.1, 158.9, 148.9, 142.4, 137.3, 135.5, 130.3, 128.2, 125.7, 123.9, 121.0, 118.9, 100.5, 80.7, 48.2, 34.8, 29.6, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 519 $[\text{M} + \text{H}]^+$.

4.4.2.7 *2'-(4'-Fluoro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclohexane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (7g)*. White solid; M.F: $\text{C}_{30}\text{H}_{25}\text{FO}_4$; mp: 160–162 °C; yield: 84%; IR (KBr, cm^{-1}): 2931, 1685, 1614, 1336, 1246, 1149; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.71–7.68 (d, $J = 8.5$ Hz, 2H), 7.65–7.62 (m, 2H), 7.20–7.16 (t, $J = 8.7$ Hz, 2H), 7.09 (s, 1H), 2.78 (s, 2H), 2.63 (s, 3H), 2.04–2.00 (m, 2H), 1.75–1.68 (m, 4H), 1.55–1.51 (m, 2H), 1.27–1.24 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.6, 164.2, 161.7, 160.0, 158.9, 149.0, 144.3, 136.3, 130.3, 128.9, 127.8, 126.8, 124.0, 120.9, 118.8, 115.7, 100.5, 80.7, 48.2, 34.8, 25.0, 21.4, 10.0; MS (ESI mass): m/z , 469 $[\text{M} + \text{H}]^+$.

4.4.2.8 *tert-Butyl-2-([1,1'-biphenyl]-4-carbonyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (7h)*. White solid; M.F: $\text{C}_{34}\text{H}_{33}\text{NO}_6$; mp: 204–207 °C; yield: 82%; IR (KBr, cm^{-1}): 2992, 1683, 1618, 1246, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.76–7.74 (d, $J = 8.5$ Hz, 2H), 7.69–7.67 (d, $J = 7.2$ Hz, 2H), 7.52–7.48 (t, $J = 7.2$ Hz, 2H), 7.44–7.40 (t, $J = 7.2$ Hz, 1H), 7.12 (s, 1H), 3.90 (bs, 2H), 3.23 (bs, 2H), 2.80 (s, 2H), 2.64 (s, 3H), 2.07–2.03 (m, 2H), 1.70–1.63 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.2, 184.7, 159.3, 154.7, 149.3, 145.4, 139.9, 138.2, 130.3, 129.7, 128.9, 128.2, 127.3, 127.0, 126.7, 121.2, 120.9, 118.7, 100.6, 79.9, 78.5, 48.3, 34.9, 28.4, 21.4, 10.0; MS (ESI mass): m/z , 552 $[\text{M} + \text{H}]^+$; HRMS: 551.23011.

4.4.2.9 *tert-Butyl-2-(4'-formyl-[1,1'-biphenyl]-4-carbonyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (7i)*. White solid; M.F: $\text{C}_{35}\text{H}_{33}\text{NO}_7$; mp: 210–212 °C; yield: 80%; IR (KBr, cm^{-1}): 2924, 1689, 1627, 1419, 1153; ^1H NMR (400 MHz, CDCl_3) δ 10.09 (s, 1H), 8.32 (s, 1H), 8.19–8.17 (d, $J = 8.2$ Hz, 2H), 8.02–8.00 (d, $J = 8.2$ Hz, 2H), 7.85–7.79 (m, 4H), 7.12 (s, 1H), 3.91 (bs, 2H), 3.24 (bs, 2H), 2.80 (s, 2H), 2.65 (s, 3H), 2.07–2.03 (m, 2H), 1.69–1.64 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.8, 191.1, 184.5, 159.4, 154.7, 149.2, 145.8, 143.8, 137.2, 135.8, 130.4, 127.9, 127.3, 124.4, 121.3, 118.8, 100.6, 79.9, 78.6, 48.1, 29.7, 28.4, 22.7, 21.4, 14.1, 10.1; MS (ESI mass): m/z , 580 $[\text{M} + \text{H}]^+$.

4.4.2.10 *tert-Butyl-2-(4'-chloro-[1,1'-biphenyl]-4-carbonyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (7j)*. White solid; M.F: $\text{C}_{34}\text{H}_{32}\text{ClNO}_6$; mp: 218–



220 °C; yield: 83%; IR (KBr, cm^{-1}): 2924, 1683, 1618, 1246, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.72–7.70 (d, $J = 8.5$ Hz, 2H), 7.1–7.59 (d, $J = 8.7$ Hz, 2H), 7.47–7.45 (d, $J = 8.7$ Hz, 2H), 7.12 (s, 1H), 3.89 (bs, 2H), 3.25 (bs, 2H), 2.80 (s, 2H), 2.64 (s, 3H), 2.07–2.01 (m, 2H), 1.66–1.70 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.1, 184.6, 159.4, 158.9, 154.7, 149.3, 144.2, 138.4, 136.5, 134.4, 130.3, 129.2, 128.5, 126.9, 124.5, 121.2, 118.7, 100.6, 79.9, 78.6, 48.1, 34.1, 29.7, 28.4, 14.1, 10.0; MS (ESI mass): m/z , 586 $[\text{M} + \text{H}]^+$.

4.4.2.11 *tert*-Butyl-3-methyl-2-(4'-methyl-[1,1'-biphenyl]-4-carbonyl)-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (**7k**). White solid; M.F: $\text{C}_{35}\text{H}_{35}\text{NO}_6$; mp: 224–227 °C; yield: 85%; IR (KBr, cm^{-1}): 2974, 1683, 1620, 1246, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.14–8.12 (d, $J = 8.2$ Hz, 2H), 7.74–7.72 (d, $J = 8.2$ Hz, 2H), 7.59–7.57 (d, $J = 8.0$ Hz, 2H), 7.31–7.29 (d, $J = 8.0$ Hz, 2H), 7.12 (s, 1H), 3.90 (bs, 2H), 3.24 (bs, 2H), 2.80 (s, 2H), 2.63 (s, 3H), 2.42 (s, 3H), 2.07–2.03 (m, 2H), 1.70–1.65 (m, 2H), 1.48 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.1, 184.7, 159.3, 158.9, 154.7, 149.4, 145.5, 138.2, 137.0, 135.9, 130.3, 129.7, 127.4, 127.1, 126.8, 124.5, 121.1, 118.6, 100.6, 79.9, 78.5, 48.1, 34.1, 29.7, 28.4, 21.2, 10.0; MS (ESI mass): m/z , 566 $[\text{M} + \text{H}]^+$.

4.4.2.12 *tert*-Butyl-3-methyl-2-(4-(naphthalen-1-yl)benzoyl)-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (**7l**). White solid; M.F: $\text{C}_{38}\text{H}_{35}\text{NO}_6$; mp: 147–148 °C; yield: 84%; IR (KBr, cm^{-1}): 2972, 1673, 1624, 1243, 1192; ^1H NMR (400 MHz, CDCl_3) δ 8.33 (s, 1H), 8.21–8.18 (d, $J = 8.2$ Hz, 2H), 7.95–7.91 (t, $J = 8.0$ Hz, 3H), 7.68–7.66 (d, $J = 8.2$ Hz, 2H), 7.59–7.46 (m, 4H), 7.16 (s, 1H), 3.90 (bs, 2H), 3.24 (bs, 2H), 2.80 (s, 2H), 2.67 (s, 3H), 2.07–2.04 (m, 2H), 1.70–1.64 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.1, 184.9, 159.3, 158.9, 154.7, 149.3, 145.5, 139.1, 136.4, 133.8, 131.2, 130.1, 129.7, 128.3, 127.7, 126.9, 126.4, 126.0, 125.6, 125.3, 124.5, 121.2, 118.7, 100.7, 79.9, 78.6, 48.1, 34.1, 29.7, 28.4, 22.6, 10.0; MS (ESI mass): m/z , 602 $[\text{M} + \text{H}]^+$.

4.4.2.13 *tert*-Butyl-2-(3',5'-dichloro-[1,1'-biphenyl]-4-carbonyl)-3-methyl-5-oxo-5,6-dihydro spiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (**7m**). White solid; M.F: $\text{C}_{34}\text{H}_{31}\text{Cl}_2\text{NO}_6$; mp: 207–208 °C; yield: 86%; IR (KBr, cm^{-1}): 2924, 1691, 1616, 1244, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 8.16–8.14 (d, $J = 8.5$ Hz, 2H), 7.70–7.68 (d, $J = 8.5$ Hz, 2H), 7.54–7.53 (d, $J = 1.7$ Hz, 2H), 7.40–7.15 (d, $J = 1.7$ Hz, 1H), 7.12 (s, 1H), 3.89 (bs, 2H), 3.25 (bs, 2H), 2.80 (s, 2H), 2.64 (s, 3H), 2.07–2.03 (m, 2H), 1.70–1.64 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.1, 184.4, 159.4, 158.9, 154.7, 149.1, 142.9, 142.6, 137.3, 135.5, 130.4, 128.0, 127.0, 125.8, 124.4, 121.3, 118.8, 100.6, 79.9, 78.6, 48.1, 34.2, 29.7, 28.4, 10.0; MS (ESI mass): m/z , 620 $[\text{M} + \text{H}]^+$.

4.4.2.14 *tert*-Butyl-2-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)-3-methyl-5-oxo-5,6-dihydrospiro[furo[3,2-g]chromene-7,4'-piperidine]-1'-carboxylate (**7n**). White solid; M.F: $\text{C}_{34}\text{H}_{32}\text{FNO}_6$; mp: 208–210 °C; yield: 87%; IR (KBr, cm^{-1}): 2922, 1681, 1622, 1244, 1153; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.71–7.69 (d, $J = 8.5$ Hz, 2H), 7.65–7.62 (m, 2H), 7.20–7.16 (t, $J = 8.7$ Hz, 2H), 7.12 (s, 1H), 3.90 (bs, 2H), 3.24 (bs, 2H), 2.80 (s, 2H), 2.64 (s, 3H), 2.07–2.03 (m, 2H), 1.70–1.66 (m, 2H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.1, 184.6, 159.3, 158.8, 154.7, 149.3, 144.5, 136.2, 132.1, 132.0, 130.3, 129.0, 128.9, 128.4,

126.8, 124.5, 121.2, 118.6, 116.0, 115.8, 100.6, 79.9, 78.6, 48.1, 28.4, 10.0; MS (ESI mass): m/z , 570 $[\text{M} + \text{H}]^+$.

4.4.2.15 2'-([1,1'-Biphenyl]-4-carbonyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (**7o**). White solid; M.F: $\text{C}_{29}\text{H}_{24}\text{O}_4$; mp: 118–120 °C; yield: 86%; IR (KBr, cm^{-1}): 2962, 1689, 1616, 1234, 1151; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.76–7.74 (d, $J = 8.5$ Hz, 2H), 7.69–7.67 (d, $J = 7.7$ Hz, 2H), 7.51–7.47 (t, $J = 7.7$ Hz, 2H), 7.44–7.39 (m, 1H), 7.05 (s, 1H), 2.91 (s, 2H), 2.63 (s, 3H), 2.14–2.09 (m, 2H), 1.92–1.88 (m, 2H), 1.75–1.68 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.8, 160.8, 158.8, 149.2, 145.5, 139.9, 136.3, 130.2, 128.9, 128.2, 127.7, 127.3, 127.0, 124.1, 121.2, 118.9, 100.7, 90.6, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 437 $[\text{M} + \text{H}]^+$.

4.4.2.16 4'-(3'-Methyl-5'-oxo-5',6'-dihydrospiro[cyclopentane-1,7'-furo[3,2-g]chromen]-2'-ylcarbonyl)-[1,1'-biphenyl]-4-carbaldehyde (**7p**). White solid; M.F: $\text{C}_{30}\text{H}_{24}\text{O}_5$; mp: 182–184 °C; yield: 88%; IR (KBr, cm^{-1}): 2958, 1693, 1622, 1290, 1213, 1143; ^1H NMR (400 MHz, CDCl_3) δ 10.09 (s, 1H), 8.32 (s, 1H), 8.19–8.16 (d, $J = 8.5$ Hz, 2H), 8.02–8.00 (d, $J = 8.5$ Hz, 2H), 7.85–7.83 (d, $J = 8.2$ Hz, 2H), 7.80–7.78 (d, $J = 8.2$ Hz, 2H), 7.04 (s, 1H), 2.91 (s, 2H), 2.65 (s, 3H), 2.14–2.09 (m, 2H), 1.93–1.88 (m, 2H), 1.77–1.68 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 191.7, 184.5, 160.8, 158.8, 149.0, 145.8, 143.7, 137.3, 135.7, 130.3, 128.2, 127.9, 127.3, 124.0, 121.2, 119.0, 100.6, 90.6, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 465 $[\text{M} + \text{H}]^+$.

4.4.2.17 2'-(4'-Chloro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (**7q**). White solid; M.F: $\text{C}_{29}\text{H}_{23}\text{ClO}_4$; mp: 138–140 °C; yield: 83%; IR (KBr, cm^{-1}): 2924, 1687, 1612, 1236, 1149; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.15–8.13 (d, $J = 8.5$ Hz, 2H), 7.72–7.70 (d, $J = 8.5$ Hz, 2H), 7.61–7.59 (d, $J = 8.7$ Hz, 2H), 7.47–7.45 (d, $J = 8.7$ Hz, 2H), 7.04 (s, 1H), 2.91 (s, 2H), 2.63 (s, 3H), 2.13–2.08 (m, 2H), 1.92–1.88 (m, 2H), 1.76–1.68 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.6, 160.8, 158.8, 149.1, 144.0, 138.4, 136.6, 134.4, 130.3, 129.1, 128.5, 127.9, 126.8, 124.0, 121.2, 119.0, 90.6, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 471 $[\text{M} + \text{H}]^+$; HRMS: 470.12822.

4.4.2.18 3'-Methyl-2'-(4'-methyl-[1,1'-biphenyl]-4-carbonyl)spiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (**7r**). White solid; M.F: $\text{C}_{30}\text{H}_{26}\text{O}_4$; mp: 126–128 °C; yield: 85%; IR (KBr, cm^{-1}): 2958, 1691, 1620, 1290, 1147; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 8.13–8.11 (d, $J = 8.5$ Hz, 2H), 7.74–7.72 (d, $J = 8.5$ Hz, 2H), 7.59–7.57 (d, $J = 8.0$ Hz, 2H), 7.31–7.29 (d, $J = 8.0$ Hz, 2H), 7.04 (s, 1H), 2.91 (s, 2H), 2.62 (s, 3H), 2.42 (s, 3H), 2.14–2.08 (m, 2H), 1.92–1.88 (m, 2H), 1.77–1.67 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.7, 160.7, 158.7, 149.2, 145.4, 138.1, 137.0, 136.0, 130.2, 129.6, 128.3, 127.1, 126.7, 124.1, 121.1, 118.9, 100.6, 90.6, 47.1, 37.5, 23.8, 21.1, 10.0; MS (EI mass): m/z , 450 $[\text{M}]^+$.

4.4.2.19 3'-Methyl-2'-(4-(naphthalen-1-yl)benzoyl)spiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'(6'H)-one (**7s**). White solid; M.F: $\text{C}_{33}\text{H}_{26}\text{O}_4$; mp: 170–172 °C; yield: 84%; IR (KBr, cm^{-1}): 2928, 1680, 1623, 1248, 1152; ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 8.20–8.18 (d, $J = 8.5$ Hz, 2H), 7.95–7.90 (m, 3H), 7.67–7.65 (d, $J = 8.5$ Hz, 2H), 7.58–7.45 (m, 4H), 7.07 (s, 1H), 2.91 (s, 2H), 2.67 (s, 3H), 2.14–2.09 (m, 2H), 1.92–1.88 (m, 2H), 1.75–1.68 (m, 4H);



^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.8, 160.7, 158.8, 149.1, 145.4, 139.0, 136.4, 133.7, 131.1, 130.0, 129.6, 128.3, 127.8, 126.9, 126.3, 125.9, 125.6, 125.3, 124.1, 121.2, 118.9, 100.7, 90.6, 47.1, 37.4, 23.8, 10.0; MS (ESI mass): m/z , 487 $[\text{M} + \text{H}]^+$.

4.4.2.20 2'-(3',5'-Dichloro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'-(6'H)-one (**7t**).

White solid; M.F: $\text{C}_{29}\text{H}_{22}\text{Cl}_2\text{O}_4$; mp: 187–188 °C; yield: 88%; IR (KBr, cm^{-1}): 2924, 1694, 1617, 1234, 1152; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.16–8.13 (d, $J = 8.5$ Hz, 2H), 7.70–7.68 (d, $J = 8.5$ Hz, 2H), 7.53 (d, $J = 1.7$ Hz, 2H), 7.40 (d, $J = 1.7$ Hz, 1H), 7.04 (s, 1H), 2.91 (s, 2H), 2.64 (s, 3H), 2.14–2.08 (m, 2H), 1.92–1.89 (m, 2H), 1.76–1.69 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.1, 184.4, 160.8, 158.7, 148.9, 142.9, 142.4, 137.3, 135.5, 130.3, 128.2, 127.9, 126.9, 125.7, 124.0, 121.2, 119.0, 100.6, 90.6, 47.1, 37.5, 23.8, 10.0; MS (ESI mass): m/z , 505 $[\text{M} + \text{H}]^+$.

4.4.2.21 2'-(4'-Fluoro-[1,1'-biphenyl]-4-carbonyl)-3'-methylspiro[cyclopentane-1,7'-furo[3,2-g]chromen]-5'-(6'H)-one (**7u**).

White solid; M.F: $\text{C}_{29}\text{H}_{23}\text{FO}_4$; mp: 138–140 °C; yield: 85%; IR (KBr, cm^{-1}): 2934, 1675, 1614, 1326, 1236, 1149; ^1H NMR (400 MHz, CDCl_3) δ 8.23 (s, 1H), 8.07–8.05 (d, $J = 8.5$ Hz, 2H), 7.63–7.61 (d, $J = 8.5$ Hz, 2H), 7.58–7.55 (t, $J = 8.7$ Hz, 2H), 7.13–7.08 (t, $J = 8.7$ Hz, 2H), 6.97 (s, 1H), 2.84 (s, 2H), 2.56 (s, 3H), 2.06–2.01 (m, 2H), 1.86–1.81 (m, 2H), 1.51 (s, 2H), 1.28 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 192.2, 184.6, 160.7, 158.7, 149.1, 144.3, 136.3, 130.3, 128.8, 127.8, 126.8, 124.0, 121.2, 118.9, 116.0, 115.7, 100.6, 90.6, 47.1, 37.5, 29.6, 23.8, 10.0; MS (ESI mass): m/z , 455 $[\text{M} + \text{H}]^+$.

5 Biological methodologies

5.1 Anti-inflammatory

The anti-inflammatory activity of synthesized compounds was studied by using inhibition of albumin denaturation technique according to Mizushima *et al.*⁴¹ and Sakat *et al.*⁴² followed with minor modifications. The reaction mixture consists of test compounds and 1% aqueous solution of bovine albumin fraction, at pH 7.4. The reaction mixture was adjusted using small amounts of 1 N HCl. The sample extracts were incubated at 37 °C for 20 min and then heated to 51 °C for 20 min, after cooling the samples the turbidity was measured at 660 nm. The percentage inhibition of protein denaturation was calculated as follows:


$$\text{Percentage inhibition} = (\text{abs control} - \text{abs sample}) \times 100 / \text{abs control}$$

with reference to correlation coefficient value (r) of 0.946

5.2 Antioxidant

5.2.1 **DPPH radical scavenging activity.** The radical scavenging activity of synthesized compounds was determined by using DPPH (2,2-diphenyl-1-picrylhydrazyl) assay following Chang *et al.*⁴³ method. The decrease in the absorption of the DPPH solution after the addition of test compound or standard antioxidant was measured at 517 nm. Ascorbic acid (10 mg mL^{-1} DMSO) was used as reference. Principle 1,1-diphenyl-2-picrylhydrazyl is a stable (in powder form) free radical with red color which turns yellow when scavenged. The DPPH assay uses this character to show free radical scavenging activity. The

scavenging reaction between (DPPH) and an antioxidant (HA) can be written as,



Antioxidants react with DPPH and reduce it to DPPH-H and as a consequence the absorbance decreases. The degree of discoloration indicates the scavenging potential of the antioxidant compounds or extracts in terms of hydrogen donating ability. The DPPH free radical scavenging assay was performed by following below method. 200 μL of 0.1 mM DPPH prepared in methanol was added to different concentrations of compounds (0.1 to 500 μM). The resulting mixture was incubated at room temperature in the dark for 15 minutes. Absorbance was observed at 517 nm. Ascorbic acid was taken as a positive control. The experiment was carried out in triplicates and percentage inhibition of the DPPH radical scavenging activity was calculated.

$$\% \text{ Inhibition} = ((A_0 - A_1)/A_0) \times 100$$

where A_0 is the absorbance of the control and A_1 is the absorbance of the sample.

5.2.2 **Hydrogen peroxide scavenging assay.** The solution of hydrogen peroxide (100 mM) was prepared by the addition of various concentrations of compound (10–200 $\mu\text{g mL}^{-1}$) to hydrogen peroxide solution (2 mL) in phosphate buffer saline of pH 7.4. Absorbance of hydrogen peroxide at 230 nm was determined after 10 min against a blank solution containing phosphate buffer without hydrogen peroxide. For each concentration, a separate blank sample was used for background subtraction. For control sample, absorbance of hydrogen peroxide solution was taken at 230 nm. The percentage inhibition activity was calculated from the formula $[(A_0 - A_1)/A_0] \times 100$, where A_0 is the absorbance of the control, and A_1 is the absorbance of test/standard taken as ascorbic acid (50–300 $\mu\text{g mL}^{-1}$).

6 Molecular modeling studies

To gain more insight into the interactions of spirofurochromanone derivatives **5a–i** and **7a–u**, molecular docking studies were performed. Crystal structure of bovine serum albumin in complex with 3,5-diiodosalicylic acid (PDB id: 4JK4)⁴⁴ and COX-2 (PDB id: 3NTG)³⁴ were downloaded from protein data bank (www.rcsb.org). Interactions of the molecules with the proteins were analyzed to identify their hypothetical binding mode. All the molecular modeling calculations were performed using Schrödinger Suite 2010 (ref. 35) on Linux platform. The protein was prepared using protein preparation module applying the default parameters, hydrogen atoms were added and unwanted water molecules were removed from the protein structure followed by hydrogen bond optimization and energy minimization. Sitemap³⁶ analysis was performed on Bovine Serum Albumin (BSA) as it had many co-crystallized ligands in it. Five top binding cavities were selected and grid



was generated around these (binding site are represented in the Table 7). In case of COX-2, grid was generated around the active site defined by the co-crystallized ligand. Receptor Van der Waals scaling for the nonpolar atoms was set to 0.9.³⁷ Molecules were built using Maestro build panel and prepared by LigPrep OPLS_2005 force. GLIDE 5.6 was used for molecular docking. Low energy conformation of the ligands was selected and docked into the grid using extra precision (XP) docking mode. Further the absorption, distribution, metabolism and excretion (ADME) properties were calculated using Qikprop module in Schrodinger Suite.

Acknowledgements

This work was supported by UGC (University Grants Commission) as UGC-MRP, Project sanction letter No: F. 43-211/2014 (SR). New Delhi, and is gratefully acknowledged. Our regards to CSIR, for their financial support to M. D. Alaparthy. We thank Head, Department of Chemistry, Osmania University, Hyderabad for providing laboratory facilities. We also thank CFRD and IICT analytical team for providing spectral analytical facilities.

References

- 1 P. Ningappa Tatti, S. Anitha, S. Shashidhara, M. Deepak and B. Sanjeevkumar, *Int. J. Pharm. Sci.*, 2012, **3**, 2314.
- 2 N. H. Grant, H. E. Alburnand and C. Kryzanasuska, *Biochem. Pharmacol.*, 1970, 715.
- 3 L. A. D. Williams, A. O'Connar, L. Latore, O. Dennis, S. Ringer, J. A. Whittaker, *et al.*, *West Indian Med. J.*, 2008, **57**, 327.
- 4 L. A. D. Williams, *West Indian Med. J.*, 2009, **58**, 191.
- 5 N. T. S. Phan, D. H. Brown and P. Styring, *Tetrahedron Lett.*, 2004, **4**, 7915.
- 6 Q. N. Chun Liu, F. Bao and J. Qiu, *Green Chem.*, 2011, **13**, 1270.
- 7 S. I. El-Desoky, F. A. Badria, M. A. Abozeid, E. A. Kandeel and A. H. Abdel-Rahman, *Med. Chem. Res.*, 2013, **22**, 2105.
- 8 P. Hezky, I. Krejci, S. Radl, J. Urbankova and P. Vachal, *Collect. Czech. Chem. Commun.*, 2000, **75**, 280.
- 9 D. Dauzonne, J. M. Gillardin, F. Lepage and R. Pointet, *Eur. J. Med. Chem.*, 1995, **30**, 53.
- 10 J. Brady, Y. Hayakawa, M. J. Smyth and S. L. Nutt, *J. Immunol.*, 2004, **172**, 2048.
- 11 J. M. Elliott, H. G. Selnick, D. A. Claremon, J. J. Baldwin, S. A. Buhrow, J. W. Butcher, C. N. Habecker, S. W. King, J. J. Lynch Jr, B. T. Phillips, G. S. Ponticello, E. M. Radzilowski, D. C. Remy, R. B. Stein, J. I. White and M. B. Young, *J. Med. Chem.*, 1992, **35**, 3973.
- 12 J. D. Rizzo, M. T. Flavin, A. Khilevich, A. Kucherenko, A. K. Sheinkman, V. Vilaychack, L. Lin, W. Chen, E. M. Greenwood, T. Pengsuparp, J. M. Pezzuto, T. M. Hughes Shf, M. Cibulski, W. A. Boulanger, R. L. Shone and Z. Q. Xu, *J. Med. Chem.*, 1996, **39**, 1303.
- 13 T. Yamakawa, H. Jona, K. Niiyama, K. Yamada, T. Iino, M. Ohkubo, H. Imamura, J. Shibata, J. Kusunoki and L. Yang, WO 2007011809 A1, 2007.
- 14 G. Morriello, L. Yang, K. Prendergast, K. Cheng, T. Jacks, W. W. S. Chan, K. D. Schleim, R. G. Smith and A. A. Patchett, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 107.
- 15 S. B. S. Nikolic, M. Brands, U. Niewohner, A. Paessens, E. Graef, K. H. Schlemmer, K. Henninger, R. Endermann, O. Weber and D. Koletzki, *US Pat.* 20020082274, 2002.
- 16 H. Abolhasani, S. Dastmalchi, M. Hamzeh-Mivehroud, B. Daraei and A. Zarghi, *Med. Chem. Res.*, 2016, **25**, 858.
- 17 J. Walsh and A. Bell, *Curr. Pharm. Des.*, 2009, **15**, 2970.
- 18 D. A. Viegas-Junior, V. da Silva Bolzani, E. J. Barreiro and C. A. Fraga, *Curr. Med. Chem.*, 2007, **14**, 1829.
- 19 M. Eric, K. N. Guantai, T. J. Egan, J. Gut, P. J. Rosenthal, P. J. Smith and K. Chibale, *Bioorg. Med. Chem.*, 2010, **18**, 8243.
- 20 J. M. Uwe Schön, S. Eichner and A. Kirschning, *Tetrahedron Lett.*, 2008, **49**, 3204.
- 21 D. Ashok, K. Sudershan and M. Khalilullah, *Green Chem. Lett. Rev.*, 2012, **5**, 121.
- 22 D. Ashok and D. Shrivani, *Tetrahedron Lett.*, 2008, **49**, 7227.
- 23 D. Ashok, D. Mohan Gandhi, A. Vikaskumar, G. Srinivas, M. Srinivas Reddy, S. SreeKanth and M. Vijjulatha, *Med. Chem. Res.*, 2016, **25**, 2882.
- 24 M. Mujahid, P. Yogeewari, D. Sriram, U. M. V. Basavanag, E. Diaz-Cervantes, L. Córdoba-Bahena, J. Robles, R. G. Gonnade, M. Karthikeyan, R. Vyas and M. Muthukrishnan, *RSC Adv.*, 2015, **5**, 106448.
- 25 D. Ashok, B. V. Lakshmi and M. Sarasija, *Lett. Org. Chem.*, 2017, **13**, 77.
- 26 R. B. Sanjay and B. W. Suresh, *Beilstein J. Org. Chem.*, 2011, **7**, 310.
- 27 B. Bartolome, V. Nunez, M. Monagas and C. Gomez-Cordoves, *Eur. Food Res. Technol.*, 2004, **218**, 173.
- 28 J. S. Wright, *Chem. Br.*, 2003, **39**, 25.
- 29 K. R. Raghavendra, N. Renuka, V. H. Kameshwar, B. Srinivasan, K. Ajay Kumar and S. Sheena, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 3621.
- 30 D. Costa, A. Gomes, S. Reis, J. L. F. C. Lima and E. Fernandes, *Life Sci.*, 2005, **76**, 2841.
- 31 D. C. Carter and J. X. Ho, *Adv. Protein Chem.*, 1994, **45**, 153.
- 32 G. Sudlow, D. J. Birkett and D. N. Wade, *Mol. Pharmacol.*, 1975, **11**, 824.
- 33 G. Sudlow, D. J. Birkett and D. N. Wade, *Mol. Pharmacol.*, 1976, **12**, 1052.
- 34 J. L. Wang, D. Limburg, M. J. Graneto, J. Springer, J. R. Hamper, S. Liao, J. L. Pawlitz, R. G. Kurumbail, T. Maziasz, J. J. Talley, J. R. Kiefer and J. Carter, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 7159.
- 35 Schrödinger, LLC, 2010, New York, Ligprep, Glide 5.6, Sitemap, Qikprop.
- 36 T. A. Halgren, *J. Chem. Inf. Model.*, 2009, **49**, 377.
- 37 R. A. Friesner, J. L. Banks and R. B. Murphy, *J. Med. Chem.*, 2004, **47**, 1739.
- 38 G.-F. Shen, T.-T. Liu, Q. Wang, M. Jiang and J.-H. Shi, *J. Photochem. Photobiol., B*, 2015, **153**, 380.
- 39 N. Rajendiran and J. Thulasidhasan, *J. Lumin.*, 2016, **31**, 1438.



- 40 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 1997, **23**, 3.
- 41 Y. Mizushima and M. Kobayashi, *J. Pharm. Pharmacol.*, 1968, **20**, 169.
- 42 S. Sakat, A. R. Juvekar and M. N. Gambhire, *Int. J. Pharm. Pharm. Sci.*, 2010, **2**, 146.
- 43 S. T. Chang, J. H. Wu, S. Y. Wang, P. L. Kang, N. S. Yang and L. F. Shyur, *J. Agric. Food Chem.*, 2001, **49**, 3420.
- 44 K. Zielinski, A. Bujacz, B. Sekula and G. Bujacz, *Int. J. Biol. Macromol.*, 2013, **60C**, 316.

